NCT06543381 2026-03-05Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell TransplantCity of Hope Medical CenterPhase 1 Recruiting15 enrolled
NCT07411586 2026-02-17Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid LeukemiaM.D. Anderson Cancer CenterPhase 1 Not yet recruiting20 enrolled